Seminars in arthritis and rheumatism最新文献

Refining RA-ILD screening: Diagnostic limitations and the emerging role of lung ultrasound 改进RA-ILD筛查：诊断局限性和肺超声的新作用

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-27 DOI: 10.1016/j.semarthrit.2025.152775

Horacio Matías Castro

引用次数: 0

Response to the letter regarding “Validation study of the SER/SEPAR screening criteria for interstitial lung disease in early rheumatoid arthritis patients” by Martinez-Castro 对Martinez-Castro关于“早期类风湿关节炎患者间质性肺病SER/SEPAR筛查标准的验证研究”的回复

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-27 DOI: 10.1016/j.semarthrit.2025.152776

Javier Narváez, Martí Aguilar-Coll

引用次数: 0

Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis 通过潜在分类分析确定免疫检查点抑制剂诱导的炎性关节炎的两个临床亚组

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-20 DOI: 10.1016/j.semarthrit.2025.152773

Laura C. Cappelli , Jamie Perin , Scott Zeger , Michelle Jones , Clifton O. Bingham , Ami A. Shah

{"title":"Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis","authors":"Laura C. Cappelli , Jamie Perin , Scott Zeger , Michelle Jones , Clifton O. Bingham , Ami A. Shah","doi":"10.1016/j.semarthrit.2025.152773","DOIUrl":"10.1016/j.semarthrit.2025.152773","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICI) for cancer treatment can cause inflammatory arthritis (IA). Since ICI-IA has a unique pathogenesis, applying categories of traditional IA may be of limited use.</div></div><div><h3>Methods</h3><div>Participants were ≥18 years old, treated with anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 agents, and had ICI-IA diagnosed by a rheumatologist. We clustered patients using latent class analysis (LCA) applied with phenotypic data from the baseline rheumatology visit. The Bayesian Information Criteria (BIC) was used to select the number of phenotypes. We compared demographics, cancer type and treatments, and IA clinical features and treatments between the estimated phenotypes. Finally, we explored differences in cytokine levels and the presence of shared epitope between the groups.</div></div><div><h3>Results</h3><div>Twenty variables were used to estimate latent classes. Two distinct phenotypes were indicated by the BIC; 77 patients were estimated to be the first phenotype and 49 in the second phenotype. The statistically significant features that distinguished the phenotypes included higher levels of all components of the CDAI, more stiffness, and more small and upper extremity joint involvement for phenotype 2. Patients in phenotype 2 were marginally more likely to require steroids during their course. There were no significant differences in cancer type, stage or ICI treatment between the phenotype groups. Baseline levels of VEGF-A were higher in phenotype 2.</div></div><div><h3>Conclusions</h3><div>Two separate phenotypes of ICI-IA were identified using LCA, the second having a more severe polyarthritis at baseline and involving the upper extremities. These subgroups provide an opportunity to identify corresponding biomarkers to predict disease outcomes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152773"},"PeriodicalIF":4.6,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effectiveness and safety of rituximab in juvenile idiopathic arthritis: Hints from the ITHACA monocentric registry 利妥昔单抗治疗青少年特发性关节炎的有效性和安全性：来自ITHACA单中心注册的提示

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-18 DOI: 10.1016/j.semarthrit.2025.152774

Maria Rosa Pellico , Marco Pandolfi , Andrea Amati , Claudia Iannone , Sabino Germinario , Stefania Costi , Francesco Baldo , Maurizio Gattinara , Elisabetta Miserocchi , Maria Gerosa , Achille Marino , Roberto Caporali , Cecilia Beatrice Chighizola

{"title":"The effectiveness and safety of rituximab in juvenile idiopathic arthritis: Hints from the ITHACA monocentric registry","authors":"Maria Rosa Pellico , Marco Pandolfi , Andrea Amati , Claudia Iannone , Sabino Germinario , Stefania Costi , Francesco Baldo , Maurizio Gattinara , Elisabetta Miserocchi , Maria Gerosa , Achille Marino , Roberto Caporali , Cecilia Beatrice Chighizola","doi":"10.1016/j.semarthrit.2025.152774","DOIUrl":"10.1016/j.semarthrit.2025.152774","url":null,"abstract":"<div><div>B cells contribute to the pathogenesis of juvenile idiopathic arthritis (JIA), suggesting a therapeutic potential for B cell depleting agent rituximab (RTX).</div><div>This retrospective study describes the effectiveness and safety of RTX in a monocentric cohort of JIA patients. Disease activity was assessed using DAS28-CRP at baseline and at each RTX infusion.</div><div>Thirty-seven JIA patients (56.8 % with polyarticular JIA) received RTX between 2008 and 2023, at a median age of 23.5 years. Most patients had a refractory disease: 45.9 % of the cohort received >2 prior biologics. The median exposure time to RTX was 2.5 years, with a median number of 5 cycles per patient and a median follow-up from first infusion of 7.44 years. At 6 months, 73 % of patients responded to RTX, and 48.6 % achieved remission. At 12 months, the trend in reducing DAS28-CRP levels persisted. ACPA positivity improved remission rates although not significantly; in most cases, uveitis did not respond to RTX. Six patients (16.2 %) discontinued RTX thanks to a prolonged remission, none requiring further biologics at a follow-up of 1.4 years. Both hypogammaglobulinemia and clinically relevant infections occurred in 27 % of the cohort. Receiving >4 RTX cycles predicted the development of hypogammaglobulinemia and/or infections (sensitivity 71.9 %, specificity 60.0 %).</div><div>Although the optimal patient selection strategy remains unclear, RTX might be regarded as an effective treatment for refractory cases, particularly in oligo/polyarticular JIA, with a manageable safety profile when exposure is limited to 4 cycles.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152774"},"PeriodicalIF":4.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging in large-vessel vasculitis: Response to Abu-Zeinah et al. 大血管炎的影像学：对Abu-Zeinah等人的反应。

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-14 DOI: 10.1016/j.semarthrit.2025.152772

Adrián Martín-Gutiérrez, Javier Loricera, Santos Castañeda, Ricardo Blanco

引用次数: 0

Incidence of gout diagnosis among participants with hyperuricemia, insights from a nationwide cohort study 痛风诊断在高尿酸血症参与者中的发病率，来自全国队列研究的见解

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-12 DOI: 10.1016/j.semarthrit.2025.152764

Shay Brikman , Oriel Perets , Liel Serfaty , Ran Abuhasira , Naomi Schlesinger , Snait Ayalon , Amir Bieber , Nadav Rappoport

{"title":"Incidence of gout diagnosis among participants with hyperuricemia, insights from a nationwide cohort study","authors":"Shay Brikman , Oriel Perets , Liel Serfaty , Ran Abuhasira , Naomi Schlesinger , Snait Ayalon , Amir Bieber , Nadav Rappoport","doi":"10.1016/j.semarthrit.2025.152764","DOIUrl":"10.1016/j.semarthrit.2025.152764","url":null,"abstract":"<div><h3>Objectives</h3><div>To examine the relationship between serum urate (SU) levels in hyperuricemic participants and the risk of developing gout.</div></div><div><h3>Methods</h3><div>A retrospective nationwide Israeli cohort study used the Clalit Health Insurance database of 473,124 individuals to identify adults aged 16 or older with at least two SU measurements exceeding 6.8 mg/dL between January 2007 and December 2022. Participants with a prior gout diagnosis or on gout medications were excluded. The primary outcome was a gout diagnosis, at least 90 days after the second record of hyperuricemia. Individuals were divided into four quartiles according to their second SU level. Survival analysis using Cox proportional hazards regression was conducted to evaluate the incidence of gout across SU quartiles.</div></div><div><h3>Results</h3><div>301,385 participants were defined as having hyperuricemia, of whom 15,055 (5 %) were diagnosed with gout after the index date. The mean/median of the second SU level of each quartile was 6.95/6.96 mg/dL, 7.20/7.20 mg/dL, 7.58/7.60 mg/dL, and 8.62/8.38 mg/dL, respectively. Participants with hyperuricemia from the highest SU quartile showed the steepest linear decline rate of gout-free survival (log-rank test P-value<0.0001). Thirteen percent (13 %) of participants in the highest SU quartile developed gout over 10 years, also showing a steady annual incidence rate of gout of 1.3 % (in that fourth quartile).</div></div><div><h3>Conclusion</h3><div>Among participants with hyperuricemia, SU level stands out as the most important risk factor associated with significant increase in the incidence of gout.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152764"},"PeriodicalIF":4.6,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144481564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PET-guided detection of relapse in large-vessel vasculitis during tocilizumab therapy: A comment on "Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice". pet引导下检测托珠单抗治疗期间大血管炎复发：对“托珠单抗治疗巨细胞动脉炎复发”的评论。407例临床患者的回顾性多中心研究”。

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-11 DOI: 10.1016/j.semarthrit.2025.152771

Khalid Abu-Zeinah, Kenneth J Warrington, Matthew J Koster

引用次数: 0

AA amyloidosis in inflammatory joint diseases: A systematic review 炎性关节疾病中的AA淀粉样变：系统综述

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-06 DOI: 10.1016/j.semarthrit.2025.152762

Binta SAVADOGO , Hanna FAHED , Jérémie SELLAM , Sophie GEORGIN-LAVIALLE , Bruno FAUTREL , Stéphane MITROVIC

{"title":"AA amyloidosis in inflammatory joint diseases: A systematic review","authors":"Binta SAVADOGO , Hanna FAHED , Jérémie SELLAM , Sophie GEORGIN-LAVIALLE , Bruno FAUTREL , Stéphane MITROVIC","doi":"10.1016/j.semarthrit.2025.152762","DOIUrl":"10.1016/j.semarthrit.2025.152762","url":null,"abstract":"<div><h3>Background</h3><div>AA amyloidosis (AAA) is a complication of chronic inflammation; the burden is expected to decrease with recent therapies. We conducted a systematic review of the incidence, prevalence, mortality and response to treatment of inflammatory joint disease (IJD)-related AAA.</div></div><div><h3>Methods</h3><div>MEDLINE, EMBASE and Cochrane library databases were searched until October 2024. Selected studies were prospective and retrospective cohorts as well as case series (≥ 10 patients) of histologically proven AAA occurring in IJD.</div></div><div><h3>Results</h3><div>From 1094 articles identified, we included 33. Substantial heterogeneity among studies was observed. Most studies (75.8 %) were published before 2010. No clear trend was identifiable in AAA incidence and mortality during the last decades. AAA prevalence rates in rheumatoid arthritis ranged from 16.7 % to 25.2 % before 2010 and decreased to 0.7 % after 2010, which suggests a potential positive role of biologic therapies. Similarly, AAA prevalence rates in ankylosing spondylitis ranged from 6.1 % to 8.5 % before 2010 and 1.1 % to 1.3 % after 2010. Immunomodulating therapies (especially biologics) seemed to improve values of AAA biomarkers, such as glomerular filtration rate and serum amyloid A level.</div></div><div><h3>Conclusions</h3><div>Our work highlights the need for more recent and comprehensive population-based epidemiological data to decipher the actual IJD-related AAA burden.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152762"},"PeriodicalIF":4.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144270750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recommendations issued by clinical practice guidelines for the implementation of healthy lifestyles in adult patients diagnosed with gout: a scoping review 临床实践指南对成年痛风患者实施健康生活方式的建议：范围审查

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-06 DOI: 10.1016/j.semarthrit.2025.152766

Diego S. Morales-Gonzales , Arihana A. Paredes-Valdiviezo , Mariano Gallo Ruelas , Milton A. Romero-Robles

{"title":"Recommendations issued by clinical practice guidelines for the implementation of healthy lifestyles in adult patients diagnosed with gout: a scoping review","authors":"Diego S. Morales-Gonzales , Arihana A. Paredes-Valdiviezo , Mariano Gallo Ruelas , Milton A. Romero-Robles","doi":"10.1016/j.semarthrit.2025.152766","DOIUrl":"10.1016/j.semarthrit.2025.152766","url":null,"abstract":"<div><div><strong>Background and Objectives:</strong> Gout is the most common inflammatory arthritis and is closely related to hyperuricemia. Although pharmacological treatment is key, lifestyle changes can help in its prevention and control. This study identified the recommendations of Clinical Practice Guidelines (CPG) on healthy habits in adults with gout and the methodology used in their development.</div><div><strong>Methods:</strong> A scoping review of CPGs published in the last 5 years in databases such as PubMed, Scopus and Web of Science, as well as repositories specialized in clinical guidelines, was performed. The PRISMA-ScR guidelines and the JBI methodology were applied.</div><div><strong>Results:</strong> Nine CPGs with recommendations on diet, physical activity and alcohol consumption were identified, with differences in their approach and level of evidence. Seven CPGs used GRADE to assess the quality of evidence and two used OXFORD. Most recommend reducing consumption of foods rich in purines and fructose, moderating alcohol, and promoting weight loss in overweight patients. No specific mental health recommendations were found. <strong>Conclusions:</strong> Lifestyle recommendations in gout CPGs, though they have a useful complementary role to play, are limited, and lack consensus. More rigorous research and updated guidelines are needed to improve patients' quality of life.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152766"},"PeriodicalIF":4.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144288897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing Raynaud’s phenomenon attack measurement tools: paper or smartphone application? 比较雷诺现象攻击测量工具：纸张还是智能手机应用？

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2025-06-06 DOI: 10.1016/j.semarthrit.2025.152765

Rachel S. Wallwork , Haomin Hu , Ami A Shah , Laura Hummers , John D Pauling , Victoria Flower , Bambang Parmanto , Andi Saptono , Robyn T Domsic

{"title":"Comparing Raynaud’s phenomenon attack measurement tools: paper or smartphone application?","authors":"Rachel S. Wallwork , Haomin Hu , Ami A Shah , Laura Hummers , John D Pauling , Victoria Flower , Bambang Parmanto , Andi Saptono , Robyn T Domsic","doi":"10.1016/j.semarthrit.2025.152765","DOIUrl":"10.1016/j.semarthrit.2025.152765","url":null,"abstract":"<div><h3>Objective</h3><div>To compare two methods of recording Raynaud’s Phenomenon (RP) attack frequency, duration and severity: the traditional Raynaud Condition Score (RCS) paper diary and a new smartphone application.</div></div><div><h3>Methods</h3><div>We conducted a multicenter study of patients with stable SSc-RP. Participants were randomized to document their RP attacks in the RCS paper diary or smartphone application for one week, at which point they were again randomized to either continue the original recording method or cross over to the other recording method for an additional week. Participants who crossed over completed a questionnaire about their experience with each method. We compared patient preference, and RP documentation by recording method.</div></div><div><h3>Results</h3><div>Fifty-five patients with stable SSc-RP were included. The 24 participants who used both modalities were significantly more likely to report “liking” the smartphone application than the paper diary (92% vs. 58%, p=0.04). There was also a non-significant difference in real-time documentation with the smartphone than the paper diary (71% vs. 38%, p=0.06). Participants reported significantly more attacks with the paper diary than with the smartphone application, however, the severity and average attack length were not significantly different.</div></div><div><h3>Conclusion</h3><div>This study supports the use of a smartphone application to document RP attack frequency, duration and severity. Not only did patients prefer the smartphone application to the paper diary, but they were also more likely to record RP attacks in real-time with the smartphone application, reducing the risk of recall bias. Future clinical trials should consider using a smartphone-based application to capture RP attacks.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152765"},"PeriodicalIF":4.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0